09:59 AM EDT, 06/26/2024 (MT Newswires) -- Taysha Gene Therapies ( TSHA ) said Wednesday it has priced an underwritten public offering of about 14.4 million shares at $2.25 per share and, in lieu of shares to some investors, pre-funded warrants to buy about 19 million shares at $2.249 per pre-funded warrant, for expected gross proceeds of $75 million.

All of the securities are being offered by the company, Taysha said.

Underwriters were given a 30-day option to buy up to an additional 15% of the shares.

The offering is expected to close Thursday.

The company's shares were falling nearly 16% in recent early Wednesday trading.

Price: 2.08, Change: -0.39, Percent Change: -15.82